Sickle cell disease (SCD)-associated priapism is characterized by decreased nitric oxide (NO) signaling and downregulated phosphodiesterase (PDE)5 protein expression and activity in the penis. Priapism is also associated with testosterone deficiency, but molecular mechanisms underlying testosterone effects in the penis in SCD are not known. Given the critical role of androgens in erection physiology and NO synthase (NOS)/PDE5 expression, we hypothesized that testosterone replacement to eugonadal testosterone levels reduces priapism by reversing impaired endothelial (e)NOS activity and molecular abnormalities involving PDE5. Adult male transgenic Berkeley sickle cell (Sickle) and wild-type (WT) mice were implanted with testosterone pellets, which release 1.2 lg testosterone/day for 21 days, or vehicle. After 21 days, animals underwent erectile function assessment followed by collection of blood for serum testosterone measurements, penes for molecular analysis, and seminal vesicles as testosterone-responsive tissue. Serum testosterone levels were measured by radioimmunoassay; protein expressions of PDE5, a-smooth muscle actin, eNOS and nNOS, and phosphorylation of PDE5 at Ser-92, eNOS at Ser-1177, neuronal (n) NOS at Ser-1412, and Akt at Ser-473 were measured by Western blot in penile tissue. Testosterone treatment reversed downregulated serum testosterone levels and increased (p < 0.05) the weight of seminal vesicles in Sickle mice to levels comparable to that of WT mice, indicating restored testosterone levels in Sickle mice. Testosterone treatment reduced (p < 0.05) prolonged detumescence in Sickle mice and normalized downregulated P-PDE5 (Ser-92), PDE5, P-eNOS (Ser-1177), and P-Akt (Ser-473) protein expressions in the Sickle mouse penis. Testosterone treatment did not affect P-nNOS (Ser-1412), eNOS, nNOS, or a-smooth muscle actin protein expressions in the Sickle mouse penis. In conclusion, in the mouse model of human SCD, increasing testosterone to eugonadal levels reduced priapic activity and reversed impaired Akt/ eNOS activity and PDE5 protein expression in the penis.
INTRODUCTION
Sickle cell disease (SCD) is a consequence of a genetic mutation involving a single amino acid substitution in the beta subunit of hemoglobin, forming hemoglobin S (Kato, 2016) . Recurrent ischemic priapism, a disorder of non-willful, excessive penile erection, associated with erectile tissue loss and erectile dysfunction, is a highly prevalent complication of SCD (Montague et al., 2003; Bivalacqua et al., 2009; Broderick et al., 2010; Anele et al., 2015) .
Reduced nitric oxide (NO)/cGMP bioavailability in the penis related to decreased endothelial NO synthase (eNOS) activity is a principal molecular defect underlying priapism in SCD (Champion et al., 2005; Bivalacqua et al., 2007 Bivalacqua et al., , 2013 Musicki et al., 2011; Lagoda et al., 2013) . Basally low levels of eNOS and NO downstream signaling in the penis in SCD are associated with decreased phosphodiesterase (PDE)5 regulatory function due to lack of the cGMP-dependent feedback control mechanism, resulting in unchecked cGMP accumulation in the penis upon neurostimulation and priapism (Champion et al., 2005; Bivalacqua et al., 2007; Burnett, 2008; Lagoda et al., 2013; Sopko et al., 2015; Silva et al., 2016) . Oxidative stress is also increased in the SCD penis associated with upregulation of NADPH oxidase and eNOS uncoupling (Kanika et al., 2010; Musicki et al., 2012; Bivalacqua et al., 2013) , while the vasoconstrictive RhoA/Rho kinase signaling pathway is downregulated, further exacerbating priapism because of reduced vasoconstriction . Other molecular mechanisms influencing cavernosal tissue reactivity have also been implicated in priapism, including excessive adenosine signaling (Mi et al., 2008) , upregulated opiorphin signaling (Fu et al., 2014) , and upregulated heme oxygenase signaling (Jin et al., 2008) .
Several clinical studies have demonstrated significantly lower serum testosterone levels in approximately 30% of male patients with SCD Morrison et al., 2015) . Testicular failure (primary hypogonadism) is established as the principal cause for this hormonal abnormality in SCD (Abbasi et al., 1976; Osegbe & Akinyanju, 1987; Parshad et al., 1994; Singhal et al., 1995; Brachet et al., 2007) . Using a mouse model of human SCD, we recently demonstrated that testosterone deficiency in SCD involves impairment in the Leydig cell steroidogenic pathway secondary to increased oxidative stress and NADPH oxidase activation in the testis . Hypogonadotropic hypogonadism (secondary hypogonadism) has also been observed in SCD patients, although this defect appears to represent patients having more severe or progressive forms of this disease (Dada & Nduka, 1980; elHazmi et al., 1991) .
The relationship between testosterone function and priapism occurrence is not well understood. Androgens play an important role in mediating normal physiologic penile erection (Podlasek et al., 2016) . Androgens exert direct effects on the expressions and functional effects of constitutive NOS enzymes in the penis (Zvara et al., 1995; Reilly et al., 1997; Marin et al., 1999; Traish & Guay, 2006) . Recent work has also documented decreased PDE5 function in the penis after castration or under conditions of hypogonadism and its restoration after testosterone replacement (Lin et al., 2001; Morelli et al., 2004; Zhang et al., 2005; Traish & Guay, 2006) . Given the critical role of androgens in erection physiology, particularly in regulating NOS and PDE5 expressions, we hypothesize that testosterone replacement to eugonadal levels may alleviate priapism in a mouse model of human SCD by reversing impaired eNOS activity and molecular abnormalities involving the PDE5 signaling system.
MATERIALS AND METHODS

Mouse model of human sickle cell disease
Four-to five-month-old male transgenic sickle cell (Sickle) and age-matched wild-type (WT) male mice were used. Berkeley Sickle mice are characterized by knockout of mouse alpha and beta globins and insertion of a single transgene that expresses human alpha and beta S globin (Paszty et al., 1997) . Sickle mice are obtained by interbreeding Sickle males with hemizygous females in-house. Breeding pairs for Sickle mice (strain number 3342) and WT mice were obtained from Jackson Laboratory (Bar Harbor, ME). Genotyping was performed by Transnetyx, Inc (Cordova, TN) . WT C57BL/6 males were used as controls because this represents the predominant background strain for the transgenic Sickle mice (Paszty et al., 1997) . Mice were pathogen-free and received routine NIH rodent chow and water. All animal procedures were conducted in accordance with the ethical standards of the Johns Hopkins University School of Medicine Guidelines for the Care and Use of Laboratory Animals, and they comply with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The numbers of mice used in each experiment are provided in the Figure Legends .
Testosterone treatment and tissue collection
Testosterone pellets (0.025 mg/pellet, Innovative Research of America, Sarasota, FL) or vehicle pellets were implanted subcutaneously into the neck area of anesthetized (2.5% isoflurane with 1 l/min O 2 flow) randomly selected WT and Sickle mice. These pellets release 1.2 lg testosterone/day for 21 days. The dose was chosen based on our preliminary studies showing that a 3-day treatment of castrated WT mice with 1.2 lg of testosterone/day resulted in physiological serum testosterone levels (1.6 AE 0.2 ng/ ml), whereas 12 lg of testosterone/day and 70 lg of testosterone/ day resulted in elevated and supraphysiological serum testosterone levels, respectively (7.9 AE 1.7 ng/ml and 13.5 AE 0.3 ng/ ml). After 21 days, mice underwent erectile function measurements, followed by blood collection for serum testosterone measurements and penis collection for molecular studies. Seminal vesicles (testosterone-responsive tissue) were removed at necropsy and weighed, and their mass per body weight was used as a bioassay for testosterone concentrations (van Roijen et al., 1997) . A separate group of mice, which did not undergo erectile function measurement, was used for penes collection for measurement of phospho (P)-eNOS (Ser-1177), P-nNOS (Ser-1412), and P-Akt (Ser-473) levels at baseline. This was done to avoid the confounding effect of repeated electrical stimulation of the cavernous nerve during ICP measurement on these parameters.
Blood sampling and testosterone measurement
After collection by cardiac puncture, blood was kept for 1 h at 4°C, then centrifuged at 3000 g for 10 min at 4°C, and serum was separated and kept at À80°C. Serum testosterone was measured by radioimmunoassay (RIA). The detection limit was 10 pg/ml and intra-and intervariabilities were 8.7% and 11.2%, respectively .
In vivo erection studies
Mice were anesthetized with intraperitoneal injection of 50 mg/kg ketamine/5 mg/kg xylazine. To monitor mean arterial pressure (MAP), the right carotid artery was cannulated with polyethylene tubing filled with heparinized saline (100 U/ml). To monitor intracavernosal pressure (ICP), the shaft of the penis was denuded of skin and fascia, and a 30-gauge needle connected by polyethylene tubing to a pressure transducer (DI-190; Dataq Instruments, Akron, OH) was inserted into the right crus. For electrically stimulated penile erections, a bipolar electrode attached to a Grass Instruments S48 stimulator (Quincy, MA) was placed around the cavernous nerve, as described previously . The cavernous nerve was stimulated at 0.3, 1, 2, and 4 V at 16 Hz with a 5-ms square-wave duration for 1 min. ICP was recorded using the DI-190 system (Dataq Instruments, Akron, OH, USA) from the start of electrical stimulation until 4 min after stimulation ended. Response parameters, calculated using MATLAB software, were corrected for baseline and expressed per MAP. Statistical analysis was performed on (i) maximum ICP at each used voltage (maximum pressure that is reached during cavernous nerve electrical stimulation); (ii) ICP area at each voltage (area under the curve, indicating the ICP response for the duration of cavernous nerve electrical stimulation); (iii) detumescence time averaged for all voltages (period from the end of cavernous nerve electrical stimulation to a point showing 50% of maximal ICP); and (iv) post-stimulated ICP/ MAP area (area under the ICP curve for 2 min after the termination of stimulation).
Western blot analysis
Penile specimens were obtained by transecting the crura of the corpus cavernosum at the point of adhesion to the lower pubic bone. Samples were snap-frozen in liquid nitrogen and stored at À80°C until processing for molecular analyses. Penes were homogenized as previously described (Hurt et al., 2002) . Protein concentration was determined using bicinchonic acid method with BSA as a standard. Homogenates (50-70 lg) were resolved on 4-20% or 7.5% Tris gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked for 1 h at room temperature in PBS (pH 7.4) containing 0.1% Tween-20 and 5% non-fat dry milk, and then probed overnight with polyclonal anti-PDE5 (1:500; Abcam Inc. Cambridge, MA, USA; catalog number ab64179), polyclonal anti-phospho (P)-Akt (Ser-473) (1:1000, Cell Signaling Technology, Beverly, MA, USA; catalog number 9271), monoclonal anti-eNOS (1:1000, BD Transduction, Laboratories, San Diego, CA, USA; catalog number 610296), polyclonal anti-nNOS (1:9000, kindly provided by Dr. Solomon Snyder at the Johns Hopkins University, Baltimore, MD) (Hurt et al., 2012) , P-PDE5 (Ser-92) (1:450, Fabgennix, International, Inc, Frisco, TX, USA; catalog number PPD5A-140AP), and monoclonal anti-a-smooth muscle actin (a-SMA, 1:1000, Abcam, catalog number 15734) antibodies. PDE5, a-SMA, P-PDE5, eNOS, and nNOS were standardized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; monoclonal antibody at 1:5000, Santa Cruz Biotechnology, catalog number 15734), and P-Akt was standardized to Akt (Cell Signaling Technology, catalog number 9272) on stripped membranes (Champion et al., 2005; Musicki et al., 2011 Musicki et al., , 2012 Musicki et al., , 2016 Bautista Niño et al., 2015) . For the analysis of P-eNOS (Ser-1177) and P-nNOS (Ser-1412), penile homogenates were partially purified for NOSs, as described previously (Hurt et al., 2002 (Hurt et al., , 2012 . Membranes were then probed with a mixture of polyclonal anti-P-eNOS (Ser-1177) (1:450, Cell signaling Technology, catalog number 9571) and polyclonal anti-PnNOS (Ser-1412) (1:7000, kindly provided by Dr. Solomon Snyder at the Johns Hopkins University, Baltimore, MD) (Hurt et al., 2012) antibodies. These membranes were stripped and probed with a mixture of monoclonal anti-eNOS (1:1000) and polyclonal anti-nNOS (1:9000) antibodies. P-eNOS (Ser-1177) and P-nNOS (Ser-1412) expressions were normalized relative to those of eNOS and nNOS, respectively, in partially purified samples. Bands were detected by horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (GE Healthcare, catalog numbers NA931V and NA934V) and quantified using NIH Image 1.29 (National Institutes of Health). All results were expressed relative to that of WT mice treated with vehicle pellets.
Statistical analysis
The program GraphPad Prism was used for statistical analysis. For analysis of ICP, serum and intratesticular testosterone, and Western blot data between treatment groups, statistical analyses were performed using one-way analysis of variance, followed by Newman-Keuls multiple comparison test. For comparison of Western blot data between WT mice treated with vehicle and each treatment group, a modified t-test was used to compare the experimental groups with the normalized control ratio. The data were expressed as the mean AE standard error of the mean (SEM). A value of p < 0.05 was considered to be statistically significant.
RESULTS
Testosterone treatment restores serum testosterone levels and seminal vesicle weight in sickle mice Serum testosterone levels were significantly lower (p < 0.05) in vehicle-treated Sickle mice as compared to vehicle-treated WT mice (Fig. 1A) , consistent with our previous report . Testosterone treatment increased serum testosterone levels in Sickle mice 3.5-fold, but due to high variability, these values did not differ significantly (p = 0.197) from the values in vehicle-treated Sickle mice. Testosterone treatment did not affect serum testosterone levels in WT mice. The weight of seminal vesicles (testosterone-responsive tissue) expressed per body weight was significantly lower (p < 0.05) in vehicle-treated Sickle mice compared to that of vehicle-treated WT mice (Fig. 1B) , consistent with lower serum testosterone levels in Sickle mice. Testosterone treatment significantly increased (p < 0.05) the weight of seminal vesicles in Sickle mice to levels comparable to that of WT mice, indicating restored testosterone concentrations in Sickle mice. Testosterone treatment also significantly increased (p < 0.05) the weight of seminal vesicles in WT mice to levels that were significantly (p < 0.05) higher than levels in Sickle mice treated with testosterone.
Testosterone treatment reduces prolonged detumescence in sickle mice
Cavernous nerve stimulation caused voltage-dependent increases in ICP/MAP ( Fig. 2A) and total ICP/MAP (Fig. 2B ) in all groups. However, maximal ICP/MAP and total ICP/MAP were similar among vehicle-treated WT and vehicle-treated Sickle mice at each voltage. Testosterone treatment did not affect the magnitude of these parameters in WT or Sickle mice. In contrast, detumescence time/MAP (Fig. 2C ) and post-stimulated ICP/ MAP area (Fig. 2D) were significantly (p < 0.05) higher in vehicle-treated Sickle compared with vehicle-treated WT mice after cavernous nerve electrical stimulation was terminated, consistent with our previous report (Silva et al., 2016) . Testosterone Figure 1 Testosterone treatment restores serum testosterone levels (A) and seminal vesicles weight (B) in Sickle mice. Mice were implanted with testosterone pellets (0.025 mg/pellet, which release 1.2 lg testosterone/day for 21 days) or vehicle pellets. After 21 days, blood and penis were collected for testosterone measurements and molecular analysis, respectively, and seminal vesicle weight was recorded. Each bar represents the mean AE SEM. *p < 0.05 vs. WT + vehicle; # p < 0.05 vs. Sickle + vehicle; +, p < 0.05 vs. WT + testosterone. n = 15/treatment. Veh = vehicle; T = testosterone.
186 Andrology, 2018, 6, 184-191 completely normalized (p < 0.05) detumescence time/MAP and post-stimulated ICP/MAP area in Sickle mice, indicating correction of prolonged post-stimulation erectile responses in these mice. Testosterone treatment did not affect detumescence time or post-stimulated area in WT mice.
Testosterone treatment restores P-PDE5 (Ser-92) and PDE5 protein expressions in the sickle mouse penis PKG-mediated phosphorylation of PDE5A at Serine-92 activates the enzyme (Rybalkin et al., 2002; Murthy, 2008; Wilson et al., 2008; Shukla et al., 2012) . Immunoblot analyses with antibodies that selectively recognize P-PDE5A (Ser-92) and PDE5A, respectively, showed that P-PDE5 (Ser-92) and PDE5 protein expressions were significantly reduced (p < 0.05) in the penis of vehicle-treated Sickle compared to vehicletreated WT mice (Fig. 3) , consistent with our previous reports (Champion et al., 2005; Bivalacqua et al., 2007; Lagoda et al., 2013; Silva et al., 2016) . Testosterone treatment of Sickle mice significantly (p < 0.05) increased P-PDE5 (Ser-92) and PDE5 protein expressions to levels comparable to WT levels, indicating that testosterone completely normalized downregulated PDE5 activation and protein expression in the Sickle mouse penis. Testosterone treatment did not affect P-PDE5 or PDE5 protein expressions in the penis of WT mice.
Testosterone treatment does not affect a-SMA protein expression in the WT or sickle mouse penis Protein expression of a-SMA, an indicator of smooth muscle content (Traish et al., 1999; Liu et al., 2017) , was not different in the vehicle-treated Sickle compared to the vehicle-treated WT mouse penis (Fig. 4) . Testosterone treatment of Sickle or WT mice also did not affect a-SMA protein expression.
Testosterone treatment restores P-eNOS (Ser-1177) and P-Akt (Ser-473) expressions, and does not affect eNOS protein expression, in the sickle mouse penis eNOS phosphorylation on Ser-1177, a positive regulatory site on eNOS (representing activated eNOS), was significantly reduced (p < 0.05) in the penis of vehicle-treated Sickle compared with that of vehicle-treated WT mice (Fig. 5) , consistent with our previous report (Musicki et al., 2011) . Testosterone treatment of Sickle mice significantly increased (p < 0.05) PeNOS (Ser-1177) to levels similar to the levels found in vehicletreated WT mice (Fig. 5A ). P-Akt was also significantly reduced (p < 0.05) in the penis of vehicle-treated Sickle compared with that of vehicle-treated WT mice, and normalized (p < 0.05) by testosterone treatment (Fig. 5B) . Testosterone did not affect PeNOS (Ser-1177) or P-Akt levels in the penis of WT mice. Protein expression of eNOS in the penis was not affected by SCD or testosterone treatment (Fig. 5C ).
Testosterone treatment does not affect P-nNOS (Ser-1412) and nNOS protein expressions in the sickle mouse penis nNOS phosphorylation on Ser-1412, a positive regulatory site on nNOS (Fig. 6A) , as well as protein expression of nNOS (Fig. 6B ) in the penis, was not affected by SCD or testosterone treatment.
DISCUSSION
The present study demonstrated that in the mouse model of human SCD, testosterone replacement restored eugonadal testosterone levels and reduced priapic activity in association with restoring eNOS activity and PDE5 activation and protein expression.
Three weeks following testosterone treatment, serum testosterone levels in Sickle mice were increased to the levels found in WT mice, indicating that the treatment resulted in eugonadal levels in these mice. Sickle mice exhibited an excessive postcavernous nerve stimulation erectile response (prolonged detumescence) (this study and Silva et al., 2016) . This excessive post-stimulation erectile response was completely reversed by testosterone treatment, suggesting decreased priapic activity in Sickle mice. Our findings are in line with a recent report of reduced priapism occurrences in testosterone-deficient men with SCD receiving long-acting testosterone undecanoate injections (Morrison et al., 2013) . Normalization of erectile function in Sickle mice by testosterone presumably resulted from normalization of tonic PDE5 function. In smooth muscle cells, PDE5 function is primarily regulated by phosphorylation. Activation of PKG leads to phosphorylation of PDE5 on Ser-92, which increases its catalytic activity apparently by increasing binding of cGMP to the regulatory domain of the enzyme (Corbin et al., 2000; Francis et al., 2002) . Here, we measured PDE5 phosphorylation as a marker of PDE5 activation and show that reduced protein expression and phosphorylation of PDE5 in cavernosal tissue from Sickle mice were completely reversed by testosterone Figure 5 Testosterone treatment restores P-eNOS (Ser-1177) (A) and P-Akt (Ser-473) (B) expressions, and does not affect eNOS protein expression (C), in the Sickle mouse penis. Upper panels are representative Western immunoblots of P-eNOS (Ser-1177), eNOS, P-Akt, Akt, and GAPDH in penes of WT vehicle-, WT testosterone-, Sickle vehicle-, and Sickle testosterone-treated mice. Lower panels represent quantitative analysis of P-eNOS (Ser-1177)/eNOS, P-Akt/Akt, and eNOS/GAPDH in penes in the same treatment groups. Each bar represents the mean AE SEM. *p < 0.05 vs. WT + vehicle; # p < 0.05 vs. Sickle + vehicle. n = 6-7/treatment. Veh, vehicle; T, testosterone. 188 Andrology, 2018, 6, 184-191 treatment. This effect of testosterone on PDE5 does not appear to be influenced by smooth muscle content in the penis, as a-SMA, expressed in vascular smooth muscle cells (Traish et al., 1999; Ryu et al., 2016; Liu et al., 2017) , was not affected by SCD or testosterone treatment. Normalized PDE5 protein expression and activation in cavernosal smooth muscle conceivably prevents excessive accumulation of cGMP upon neurostimulation, lessening priapic activity.
Studies in experimental animal models, as well as clinical investigations, indicate that androgens positively affect PDE5 expression and activity. PDE5 function decreases in the penis after castration or under conditions of hypogonadism and is restored after testosterone replacement (Traish et al., 1999; Morelli et al., 2004; Zhang et al., 2005; Traish & Guay, 2006) . These findings suggest that hypogonadism in patients with SCD may correlate with PDE5 downregulation, which makes them susceptible to priapism. The mechanism of androgen effect on PDE5 expression and activity is, however, not well understood. A consensus sequence for the androgen receptor was described in the PDE5 promoter (Lin et al., 2001) , suggesting that androgens positively regulate expression and functional activity of PDE5 gene. However, recent studies failed to find androgen response elements in the rat PDE5A gene (Yang et al., 2009; Lin et al., 2013) . Another possible explanation for the upregulatory effect of testosterone on PDE5 expression is that this effect is secondary, due to testosterone-induced increase in the expressions and function of constitutive NOS enzymes (Reilly et al., 1997; Marin et al., 1999; Traish et al., 2007; Podlasek et al., 2016) . Upregulated NOS, through increased accumulation of intracellular cGMP, may increase PDE5 protein expression through cGMPresponsive sequences in the PDE5 promoter (Lin et al., 2001 (Lin et al., , 2002 .
In the vasculature, androgens have been shown to modulate NOS function via both genomic and non-genomic mechanisms (Cai et al., 2016) . Androgens elicit a direct genomic-mediated action through the activation of classic androgen receptors in endothelial cells (Cai et al., 2016) . Androgens also exert nongenomic action via interactions with putative membrane androgen receptors (Heinlein & Chang, 2002) . Via non-genomic mechanisms, testosterone at physiologic concentrations stimulates eNOS activity by phosphorylation on Ser-1177 in human aortic endothelial cells (Yu et al., 2010 (Yu et al., , 2012 and human umbilical vein endothelial cells (Goglia et al., 2010; Ota et al., 2012) . This effect of testosterone is mediated by activation of the c-Src/phosphatidylinositol (PI3) kinase/Akt pathway (Goglia et al., 2010; Yu et al., 2012) . Testosterone-induced post-translational activation of eNOS by phosphorylation has also been recently described in the penis of castrated rats after treatment with testosterone for 1 month (Li et al., 2016) . Here, we show that downregulated PeNOS (Ser-1177) and P-Akt, an activator of P-eNOS in the penis (Hurt et al., 2002) , were normalized in the Sickle mouse penis by treatment with physiologic doses of testosterone, in parallel with normalization of PDE5 protein expression and activation. Based on these findings, we propose that normalization of testosterone levels in Sickle mice and resulting upregulation of eNOS activity in the penis causes PDE5 upregulation, and consequently decreases priapism susceptibility.
Interestingly, in human umbilical vein endothelial cells, supraphysiologic doses of testosterone decrease eNOS phosphorylation on Ser-1177, eNOS activity, and NO synthesis (Goglia et al., 2010; Skogastierna et al., 2014) . This may partially explain findings described in several case reports in humans that at excessive dosing, testosterone may trigger priapism rather than reduce it (Shergill et al., 2003; Ichioka et al., 2006; Donaldson et al., 2012) . We found no effect of testosterone on protein expressions of eNOS and nNOS, or nNOS phosphorylation on Ser-1412, a positive regulatory site on nNOS, suggesting that the beneficial effects of testosterone in reducing priapism in the Sickle mouse penis are apparently not mediated by increased eNOS or nNOS protein contents or nNOS phosphorylation.
We acknowledge several limitations in our study. We acknowledge that additional experimental approaches may offer further confirmation that testosterone normalizes PDE5 gene and protein expression. Such approaches include expression analysis of PDE5 mRNA and cGMP measurements by assay, although it is known that the latter is difficult to perform in cells and particularly in whole tissues. Although we focused on a putative testosterone effect on PDE5 as regulated by post-translational activation of constitutive NOS enzymes, other testosteronemediated effects may also be involved, such as reduction in oxidative stress (Li et al., 2016; Pongkan et al., 2016) or normalization of vasoconstriction (Wingard et al., 2003) . We recently showed that priapism in transgenic Sickle mice is associated with a lack of RhoA/ROCK-mediated vasoconstriction of the penile vasculature . Basal release of NO is necessary to maintain RhoA/Rho kinase-dependent contractile function; chronic NO deficiency, by decreasing PKGmediated phosphorylation of RhoA (Ser-188) (Rolli-Derkinderen et al., 2005) , is associated with decreased RhoA/Rho kinasedependent calcium sensitization (Sauzeau et al., 2003) . It is possible that by achieving balanced NO/cGMP signaling in the penis, testosterone may upregulate the RhoA/Rho kinase contractile pathway, thereby preventing excessive vasorelaxation and preserving homeostasis in the Sickle mouse penis. These topics await further investigation.
In summary, our findings suggest that hypogonadism exacerbates an already aberrant molecular signaling mechanism in SCD-associated priapism, while preservation of normative testosterone levels reduces priapic activity by promoting molecular mechanisms that favor normal erection responses. An improved understanding of molecular mechanisms involved in the pathogenesis of SCD-associated priapism will conceivably offer new targeted therapies for treatment.
